Oppenheimer analyst Mark Breidenbach lowered the price target on Cue Biopharma (NASDAQ: CUE) to $10.00 (from $26.00) while maintaining an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE